An analysis of the effects of smoking and other cardiovascular risk factors on obliteration rates after arteriovenous malformation radiosurgery

Citation
A. Bhatnagar et al., An analysis of the effects of smoking and other cardiovascular risk factors on obliteration rates after arteriovenous malformation radiosurgery, INT J RAD O, 51(4), 2001, pp. 969-973
Citations number
25
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
ISSN journal
03603016 → ACNP
Volume
51
Issue
4
Year of publication
2001
Pages
969 - 973
Database
ISI
SICI code
0360-3016(20011115)51:4<969:AAOTEO>2.0.ZU;2-A
Abstract
Purpose: To assess the relationships of smoking and other cardiovascular di sease risk factors (hypertension, diabetes, hypercholesterolemia, and gende r) to rates of radiosurgery-induced obliteration of arteriovenous malformat ions (AVM). Methods and Materials: We evaluated follow-up imaging and clinical data in 329 AVM patients who received gamma knife radiosurgery at the University of Pittsburgh between 1987 and 1994. There were 113 smokers, 29 hypertensives , 5 diabetics, 4 hypercholesterolemics, 159 male patients, and 170 female p atients. All patients had regular clinical or imaging follow-up for a minim um of 3 years after radiosurgery. Results: Multivariate analysis showed that smoking had no effect on AVM obl iteration (p > 0.43). Hypertension, diabetes, and hypercholesterolemia had no discernible effect on AVM obliteration in this study (p > 0.78). However , females aged 12-49 had a statistically significant lower in-field obliter ation rate than males (78% vs. 89%,p = 0.0102). Conclusion: Smoking has no effect on AVM obliteration. Hypertension, diabet es, and hypercholesterolemia had no discernible effect in this study. Furth er study is needed to establish whether estrogen has a vascular protective effect that could partially limit radiosurgical AVM obliteration, as sugges ted by this study. (C) 2001 Elsevier Science Inc.